Atorvastatin treatment modulates the interaction between leptin and adiponectin, and the clinical parameters in patients with type II diabetes

Sayer I. Al-Azzam, Asem M. Alkhateeb, Karem H. Alzoubi, Raya N. Alzayadeen, Mera A. Ababneh, Omar F. Khabour

Research output: Contribution to journalArticle

8 Citations (Scopus)

Abstract

The aim of this study was to examine the effect of atorvastatin treatment on levels of leptin, adiponectin and insulin resistance, and their correlation with clinical parameters, in patients with type II diabetes. Patients with diabetes (n=394) were divided into two groups, comprising 161 patients who received 20 mg/day atorvastatin (statin group), and 233 patients who did not receive statins (statin-free group). The results showed that atorvastatin treatment of patients with diabetes was not associated with changes in leptin, adiponectin, the leptin/adiponectin (L/A) ratio or homeostasis model assessment-insulin resistance (HOMA-IR). However, low-density lipoprotein cholesterol (LDL-C), triglycerides (TG) and total cholesterol (Tchol) were positively correlated with leptin and L/A ratio in the statin group only (P<0.05). By contrast, high-density lipoprotein cholesterol (HDL-C) showed a significant positive correlation with adiponectin in the statin and statin-free groups (P<0.05). Additionally, a positive correlation was found between HOMA-IR and glycated hemoglobin (HbA1c), and TG, in both groups, whereas Tchol was positively correlated with HOMA-IR in the statin group only (P<0.05). When multivariate analysis was performed with HOMA-IR as the dependent variable, and with adjustment for age, body mass index (BMI) and waist circumference, HbA1c was found to be a significant predictor of HOMA-IR or insulin resistance. In conclusion, atorvastatin treatment may have several effects on the interaction between leptin and adiponectin, and on clinical parameters in patients with type II diabetes.

Original languageEnglish
Pages (from-to)1565-1569
Number of pages5
JournalExperimental and Therapeutic Medicine
Volume6
Issue number6
DOIs
Publication statusPublished - 2013
Externally publishedYes

Fingerprint

Hydroxymethylglutaryl-CoA Reductase Inhibitors
Adiponectin
Leptin
Type 2 Diabetes Mellitus
Insulin Resistance
Homeostasis
Therapeutics
Cholesterol
Glycosylated Hemoglobin A
Waist Circumference
Atorvastatin Calcium
LDL Cholesterol
HDL Cholesterol
Triglycerides
Body Mass Index
Multivariate Analysis

Keywords

  • Adiponectin
  • Insulin resistance
  • Leptin
  • Lipid panel
  • Statins

ASJC Scopus subject areas

  • Medicine(all)
  • Cancer Research
  • Immunology and Microbiology (miscellaneous)

Cite this

Atorvastatin treatment modulates the interaction between leptin and adiponectin, and the clinical parameters in patients with type II diabetes. / Al-Azzam, Sayer I.; Alkhateeb, Asem M.; Alzoubi, Karem H.; Alzayadeen, Raya N.; Ababneh, Mera A.; Khabour, Omar F.

In: Experimental and Therapeutic Medicine, Vol. 6, No. 6, 2013, p. 1565-1569.

Research output: Contribution to journalArticle

Al-Azzam, Sayer I. ; Alkhateeb, Asem M. ; Alzoubi, Karem H. ; Alzayadeen, Raya N. ; Ababneh, Mera A. ; Khabour, Omar F. / Atorvastatin treatment modulates the interaction between leptin and adiponectin, and the clinical parameters in patients with type II diabetes. In: Experimental and Therapeutic Medicine. 2013 ; Vol. 6, No. 6. pp. 1565-1569.
@article{cfba50c6a7a645c59e6b4673d28fedb0,
title = "Atorvastatin treatment modulates the interaction between leptin and adiponectin, and the clinical parameters in patients with type II diabetes",
abstract = "The aim of this study was to examine the effect of atorvastatin treatment on levels of leptin, adiponectin and insulin resistance, and their correlation with clinical parameters, in patients with type II diabetes. Patients with diabetes (n=394) were divided into two groups, comprising 161 patients who received 20 mg/day atorvastatin (statin group), and 233 patients who did not receive statins (statin-free group). The results showed that atorvastatin treatment of patients with diabetes was not associated with changes in leptin, adiponectin, the leptin/adiponectin (L/A) ratio or homeostasis model assessment-insulin resistance (HOMA-IR). However, low-density lipoprotein cholesterol (LDL-C), triglycerides (TG) and total cholesterol (Tchol) were positively correlated with leptin and L/A ratio in the statin group only (P<0.05). By contrast, high-density lipoprotein cholesterol (HDL-C) showed a significant positive correlation with adiponectin in the statin and statin-free groups (P<0.05). Additionally, a positive correlation was found between HOMA-IR and glycated hemoglobin (HbA1c), and TG, in both groups, whereas Tchol was positively correlated with HOMA-IR in the statin group only (P<0.05). When multivariate analysis was performed with HOMA-IR as the dependent variable, and with adjustment for age, body mass index (BMI) and waist circumference, HbA1c was found to be a significant predictor of HOMA-IR or insulin resistance. In conclusion, atorvastatin treatment may have several effects on the interaction between leptin and adiponectin, and on clinical parameters in patients with type II diabetes.",
keywords = "Adiponectin, Insulin resistance, Leptin, Lipid panel, Statins",
author = "Al-Azzam, {Sayer I.} and Alkhateeb, {Asem M.} and Alzoubi, {Karem H.} and Alzayadeen, {Raya N.} and Ababneh, {Mera A.} and Khabour, {Omar F.}",
year = "2013",
doi = "10.3892/etm.2013.1347",
language = "English",
volume = "6",
pages = "1565--1569",
journal = "Experimental and Therapeutic Medicine",
issn = "1792-0981",
publisher = "Spandidos Publications",
number = "6",

}

TY - JOUR

T1 - Atorvastatin treatment modulates the interaction between leptin and adiponectin, and the clinical parameters in patients with type II diabetes

AU - Al-Azzam, Sayer I.

AU - Alkhateeb, Asem M.

AU - Alzoubi, Karem H.

AU - Alzayadeen, Raya N.

AU - Ababneh, Mera A.

AU - Khabour, Omar F.

PY - 2013

Y1 - 2013

N2 - The aim of this study was to examine the effect of atorvastatin treatment on levels of leptin, adiponectin and insulin resistance, and their correlation with clinical parameters, in patients with type II diabetes. Patients with diabetes (n=394) were divided into two groups, comprising 161 patients who received 20 mg/day atorvastatin (statin group), and 233 patients who did not receive statins (statin-free group). The results showed that atorvastatin treatment of patients with diabetes was not associated with changes in leptin, adiponectin, the leptin/adiponectin (L/A) ratio or homeostasis model assessment-insulin resistance (HOMA-IR). However, low-density lipoprotein cholesterol (LDL-C), triglycerides (TG) and total cholesterol (Tchol) were positively correlated with leptin and L/A ratio in the statin group only (P<0.05). By contrast, high-density lipoprotein cholesterol (HDL-C) showed a significant positive correlation with adiponectin in the statin and statin-free groups (P<0.05). Additionally, a positive correlation was found between HOMA-IR and glycated hemoglobin (HbA1c), and TG, in both groups, whereas Tchol was positively correlated with HOMA-IR in the statin group only (P<0.05). When multivariate analysis was performed with HOMA-IR as the dependent variable, and with adjustment for age, body mass index (BMI) and waist circumference, HbA1c was found to be a significant predictor of HOMA-IR or insulin resistance. In conclusion, atorvastatin treatment may have several effects on the interaction between leptin and adiponectin, and on clinical parameters in patients with type II diabetes.

AB - The aim of this study was to examine the effect of atorvastatin treatment on levels of leptin, adiponectin and insulin resistance, and their correlation with clinical parameters, in patients with type II diabetes. Patients with diabetes (n=394) were divided into two groups, comprising 161 patients who received 20 mg/day atorvastatin (statin group), and 233 patients who did not receive statins (statin-free group). The results showed that atorvastatin treatment of patients with diabetes was not associated with changes in leptin, adiponectin, the leptin/adiponectin (L/A) ratio or homeostasis model assessment-insulin resistance (HOMA-IR). However, low-density lipoprotein cholesterol (LDL-C), triglycerides (TG) and total cholesterol (Tchol) were positively correlated with leptin and L/A ratio in the statin group only (P<0.05). By contrast, high-density lipoprotein cholesterol (HDL-C) showed a significant positive correlation with adiponectin in the statin and statin-free groups (P<0.05). Additionally, a positive correlation was found between HOMA-IR and glycated hemoglobin (HbA1c), and TG, in both groups, whereas Tchol was positively correlated with HOMA-IR in the statin group only (P<0.05). When multivariate analysis was performed with HOMA-IR as the dependent variable, and with adjustment for age, body mass index (BMI) and waist circumference, HbA1c was found to be a significant predictor of HOMA-IR or insulin resistance. In conclusion, atorvastatin treatment may have several effects on the interaction between leptin and adiponectin, and on clinical parameters in patients with type II diabetes.

KW - Adiponectin

KW - Insulin resistance

KW - Leptin

KW - Lipid panel

KW - Statins

UR - http://www.scopus.com/inward/record.url?scp=84888423801&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84888423801&partnerID=8YFLogxK

U2 - 10.3892/etm.2013.1347

DO - 10.3892/etm.2013.1347

M3 - Article

VL - 6

SP - 1565

EP - 1569

JO - Experimental and Therapeutic Medicine

JF - Experimental and Therapeutic Medicine

SN - 1792-0981

IS - 6

ER -